American Research & Development Corporation (ARD) was an American investment firm founded in Boston in 1946. Considered the first modern venture capital firm in the United States, the firm set industry precedents by combining institutional capital with professional selection and oversight of early-stage ventures.
ARD emerged from efforts led by MIT president Karl Compton and Boston Federal Reserve president Ralph Flanders, who concluded that a dedicated fund for new industries could reverse New England's industrial decline. Georges Doriot, a Harvard Business School professor, served as president for its 25-year existence. The firm was organized as a publicly traded closed-end fund, raising $3.5 million from insurers, investment trusts, and university endowments in its initial offering. Returns from its first investments, particularly High Voltage Engineering Corporation and Ionics, convinced ARD to focus on research-based ventures.
The firm's 1957 investment of $70,000 in Digital Equipment Corporation (DEC) became the defining success of early venture capital. DEC developed the minicomputer and grew to become Massachusetts' largest employer and the United States' second-largest computer maker; ARD's stake reached $355 million by 1971. Over its lifetime, ARD generated annualized returns of 14.7 percent, half of which came from the investment in DEC.
ARD faced mounting competition from limited partnerships, which could offer equity compensation to investment professionals in ways SEC regulations prohibited for public companies. After failing to establish a succession plan, the firm merged with Textron in 1972 and ceased operations in 1976. Several ARD alumni founded influential venture firms, including Greylock Partners and Fidelity Ventures, while Doriot's former students financed Fairchild Semiconductor and Intel.
Organization
ARD has been described as the "first true venture capital firm": it was the first American firm to choose companies on behalf of investors, rather than drawing from family wealth. Earlier venture investors like J.H. Whitney & Company and Rockefeller Brothers deployed family wealth through hired staff; ARD raised capital from insurers, investment trusts, and university endowments, then made investment decisions through a small team of salaried professionals. The principle that outside investors would supply capital while professionals selected firms became the template for the modern venture capital industry.
ARD was organized as a closed-end fund under Section 12(d)(1) of the Investment Company Act of 1940, giving it a permanent capital base. The founders chose this structure because venture investments required patience, and a closed-end fund faced no redemption pressure from shareholders. ARD's average investment horizon was 6.5 years, with some requiring a decade or longer.
In this and several other respects, ARD differed from modern venture firms. It was a publicly traded company, subject to SEC disclosure requirements that portfolio companies found burdensome. It had no mechanism to share investment gains with staff; SEC rules prohibited the stock options that later became standard in limited partnerships. And its closed-end structure created pressure to generate current income. ARD financed many investments through convertible debt or convertible preferred stock rather than common equity, and charged management fees to portfolio companies.
Investing approach
Georges Doriot's approach emphasized founders over their business ideas. "An average idea in the hands of an able man is worth much more than an outstanding idea in the possession of a person with only average ability," he wrote in ARD's 1949 annual report. ARD documentation stated its intent "to invest only in situations and companies where able management by men of competence and integrity seems assured." Doriot asserted that "in practically no case have we had what I would call a technical failure. It has been human failures."
ARD was highly selective. Over its lifetime, the firm reviewed nearly 6,884 proposals and funded 120 companies, a lifetime acceptance rate of 1.7 percent, which never exceeded 4 percent in any five-year period. ARD concentrated on technology-based ventures, particularly in fields where patent protection could help small firms compete against established corporations. 73 percent of its investments were in R&D-intensive sectors: chemicals, scientific instruments, industrial equipment, and electronics. In its first five years over three-quarters of ARD's investments were in Massachusetts or the eastern seaboard, reflecting both the founders' regional development mission and the practical advantages of local governance.
ARD required board representation to monitor investments and intervene when necessary. Doriot or other ARD officers joined the boards of portfolio companies; Karl Compton and Merrill Griswold served on Tracerlab's board, while Doriot and Compton sat on the boards of High Voltage Engineering and Ionics. This "Doriot style" of active investment meant providing advice and assistance without unduly restricting founders' autonomy.
ARD staged its investments, providing limited initial capital and additional funding only as companies demonstrated progress. Doriot explained the rationale: "in the hands of an inexperienced person commitments of all types are often made quite recklessly and capital has a way of disappearing at a remarkable high rate of speed." When necessary, ARD took more drastic measures—it acquired voting control of Circo Products in 1950 and replaced top management after three years of stagnation.
Companies funded by ARD were considered "members of the family," and Doriot was reluctant to sell them. His formula was to exit only when "hope seems gone" or when "all is right but not outstanding" or when "the best growth period is behind." This patience reflected his conviction that venture capital's purpose was "not one of 'making money' but rather financing 'noble' ideas." ARD's founders also understood that a diversified portfolio could tolerate failures if a few investments succeeded dramatically.
Origins
ARD emerged from concerns about New England's economic decline. The textile and manufacturing industries that had anchored the region were leaving for the South, and employment in Massachusetts cotton manufacturing alone fell from 124,000 in 1919 to under 30,000 by 1940. Civic leaders sought mechanisms to commercialize research from local universities—particularly MIT—as a basis for industrial revival.
Karl T. Compton, a physicist who became MIT's president in 1930, believed scientific research could drive regional growth. In 1934 he proposed a program called "Put Science to Work," arguing against prevailing sentiment that blamed labor-saving technology for unemployment. "New industries are like babies," Compton wrote in the New York Times Magazine: "they need shelter and nourishment, which they take in the form of patent protection, financing, and the chance of reasonable profits. But, before all, they need to be born, and their parents are science and invention."
The New England Council, a regional business association, embraced the idea and asked Compton to chair a "New Products Committee" in 1939 to examine how technology might reverse industrial decline. The committee brought Compton together with Ralph Flanders, an industrialist and president of the Council; Merrill Griswold, chairman of Massachusetts Investors Trust; Donald David, dean of Harvard Business School; and Georges Doriot, a Harvard Business School professor who chaired a subcommittee on "Development Procedures and Venture Capital."
The committee identified a structural problem: approximately 45 percent of New England wealth was held by banks, insurers, and trusts legally barred or culturally averse to risky investments. Capital was not scarce, but the capacity to evaluate startups was. As Griswold explained, his firm would "under no circumstances directly make investments in risky new undertakings for the reason that we are not staffed for that purpose." The committee concluded that a specialized intermediary could bridge this gap—assembling a diversified portfolio where, even if several investments failed, "the others, the hope is, will more than make up for it."
World War II suspended these plans but reinforced the case for organized venture capital. Doriot served as a brigadier general directing research and development for the Army Quartermaster General. Compton worked with the Office of Scientific Research and Development, which coordinated wartime research producing radar, mass-produced penicillin, and the atomic bomb. Federal research spending concentrated technical expertise in the Boston area. Appointed president of the Boston Federal Reserve in 1944, Flanders became further convinced that lack of financial support for new industries would harm postwar prosperity. In 1944, he proposed a new corporate entity to ensure a "reasonably high birth rate of new undertakings." Following the Japanese surrender, Compton gathered his colleagues from the New Products Committee and persuaded them to act.
Company history Postwar launch ARD was incorporated on June 6, 1946. The founders' first choice for president was Doriot, but he remained in Army service. In the interim, they named him chairman and installed Flanders—then running for the U.S. Senate—as acting president. When Flanders won his Senate race in November and Doriot was released from the Army in December, Doriot assumed the presidency.
ARD required SEC exemptions from the Investment Company Act of 1940 to proceed. The Act restricted investment companies from owning controlling stakes in portfolio firms. The firm sought $5 million through a public offering at $25 per share. Wall Street was skeptical and major underwriters declined, viewing ARD as "more of a social experiment than a profit-seeking entity." Two second-tier investment houses agreed to sponsor the offering, but only on a "best-efforts" basis—they would attempt to sell the shares but would not backstop any shortfall with their own capital.
By February 1947, ARD had raised $3.5 million. Half of its capital came from the Massachusetts Investors Trust, John Hancock Life Insurance, and four university endowments: MIT, Rice University, the University of Pennsylvania, and the University of Rochester. Individuals, primarily directors and associates, provided the rest.
Early investments and operations
In late 1946, ARD's first investments reflected both its mission and limited capitalization. Two investments were in startups developing new technologies. Tracerlab, founded by MIT graduate William Barbour to manufacture radiation measurement equipment, was near bankruptcy after being rejected by Boston investors and refused Wall Street terms demanding 51 percent equity. ARD provided $150,000 on more favorable terms. High Voltage Engineering Corporation, founded by two MIT faculty to develop particle accelerators for cancer treatment, received $200,000 and began operations in a garage near Harvard Square. ARD made a third investment of $150,000 in Circo Products, a Cleveland company developing automobile transmission solvents—not a startup but an established company filing patents since the 1930s.